Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 304, Issue 1, 2013, Pages

  Leduc, Martin ^a,b   Hou, Xin ^a   Hamel, David ^a,b   Sanchez, Melanie ^c   Quiniou, Christiane ^a,b   Honoré, Jean Claude ^a   Roy, Olivier ^b   Madaan, Ankush ^a,c   Lubell, William ^b   Varma, Daya R ^c   Mancini, Joseph ^a   Duhamel, François ^b   Peri, Krishna G ^d   Pichette, Vincent ^b   Heveker, Nikolaus ^a,b   Chemtob, Sylvain ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d Theratechnologies Inc   (Canada)

Author keywords

Allosteric modulator; Cisplatin; Renal artery occlusion

Indexed keywords

BETA ARRESTIN; CISPLATIN; CYCLIC AMP; FIBROBLAST GROWTH FACTOR 2; HEME OXYGENASE 1; INTERLEUKIN 6; MESSENGER RNA; PEPTIDOMIMETIC AGENT; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROTEIN BCL 2; THG 21329; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY ARTERY STENOSIS; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; URINE VOLUME;

ACUTE KIDNEY INJURY; ANIMALS; CISPLATIN; CYCLIC AMP; DISEASE MODELS, ANIMAL; DOGS; FEMALE; FIBROBLAST GROWTH FACTOR 2; GLOMERULAR FILTRATION RATE; HEK293 CELLS; HEME OXYGENASE-1; HUMANS; INTERLEUKIN-6; KIDNEY; MALE; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RECOVERY OF FUNCTION; RENAL PLASMA FLOW; SAPHENOUS VEIN; SWINE;

EID: 84871889691     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00138.2012     Document Type: Article

References (52)

1. Aoudjit L, Potapov A, Takano T. Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor. Am J Physiol Renal Physiol 290: F1534-F1542, 2006.
2. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, Rosenbaum DM, Fung JJ, Choi HJ, Thian FS, Kobilka TS, Puglisi JD, Weis WI, Pardo L, Prosser RS, Mueller L, Kobilka BK. Ligand-specific regulation of the extracellular surface of a G protein-coupled receptor. Nature 463: 108-112, 2010.
3. Breyer MD, Breyer RM. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 63: 579-605, 2001.
4. Breyer MD, Davis L, Jacobson HR, Breyer RM. Differential localization of prostaglandin E receptor subtypes in human kidney. Am J Physiol Renal Fluid Electrolyte Physiol 270: F912-F918, 1996.
5. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 103: 1492-1497, 2006.
6. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human 2-adrenergic G protein-coupled receptor. Science 318: 1258-1265, 2007.
7. de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, Takala J, Sprung C, Cantraine F. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 26: 915-921, 2000.
8. Farman N, Pradelles P, Bonvalet JP. PGE2, PGF2 alpha, 6-keto-PGF1 alpha, and TxB2 synthesis along the rabbit nephron. Am J Physiol Renal Fluid Electrolyte Physiol 252: F53-F59, 1987.
9. Ferenbach DA, Kluth DC, Hughes J. Hemeoxygenase-1 and renal ischaemia-reperfusion injury. Nephron Exp Nephrol 115: e33-e37, 2010.
10. Friis UG, Stubbe J, Uhrenholt TR, Svenningsen P, Nusing RM, Skott O, Jensen BL. Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells. Am J Physiol Renal Physiol 289: F989-F997, 2005.
11. Fujino H, Regan JW. EP4 prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol Pharmacol 69: 5-10, 2006.
12. Galandrin S, Oligny-Longpre G, Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28: 423-430, 2007.
13. Goupil E, Tassy D, Bourguet C, Quiniou C, Wisehart V, Petrin D, Le Gouill C, Devost D, Zingg HH, Bouvier M, Saragovi HU, Chemtob S, Lubell WD, Claing A, Hebert TE, Laporte SA. A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway. J Biol Chem 285: 25624-25636, 2010.
14. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M. A peptide derived from a 2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271: 16384-16392, 1996.
15. Ivey KN, Srivastava D. The paradoxical patent ductus arteriosus. J Clin Invest 116: 2863-2865, 2006.
16. Jensen BL, Stubbe J, Hansen PB, Andreasen D, Skott O. Localization of prostaglandin E2, EP2, and EP4 receptors in the rat kidney. Am J Physiol Renal Physiol 280: F1001-F1009, 2001.
17. Kellum JA. Acute kidney injury. Crit Care Med 36: S141-S145, 2008.
18. Kellum JA, Angus DC. Patients are dying of acute renal failure. Crit Care Med 30: 2156-2157, 2002.
19. Kenakin T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 28: 407-415, 2007.
20. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 72: 1393-1401, 2007.
21. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24: 346-354, 2003.
22. Kenakin TP. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov 8: 617-626, 2009.
23. Kielar ML, John R, Bennett M, Richardson JA, Shelton JM, Chen L, Jeyarajah DR, Zhou XJ, Zhou H, Chiquett B, Nagami GT, Lu CY. Maladaptive role of IL-6 in ischemic acute renal failure. J Am Soc Nephrol 16: 3315-3325, 2005.
24. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 365: 417-430, 2005.
25. Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28: 382-389, 2007.
26. Leduc M, Breton B, Gales C, Le Gouill C, Bouvier M, Chemtob S, Heveker N. Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J Pharmacol Exp Ther 331: 297-307, 2009.
27. Lydford SJ, McKechnie KC, Dougall IG. Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br J Pharmacol 117: 13-20, 1996.
28. Ma Q, Devarajan P. Induction of proapoptotic Daxx following ischemic acute kidney injury. Kidney Int 74: 310-318, 2008.
29. Mathur VS. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. Rev Cardiovasc Med 2 Suppl 1: S4-S8, 2001.
30. Matthews JC. Fundamentals of Receptor, Enzyme, and Transport Kinetics. Boca Raton, FL: CRC Press, 1993.
31. May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47: 1-51, 2007.
32. Miller Q, Peyton BD, Cohn EJ, Holmes GF, Harlin SA, Bird ET, Harre JG, Miller ML, Riley KD, Hogan MB, Taylor A. The effects of intraoperative fenoldopam on renal blood flow and tubular function following suprarenal aortic cross-clamping. Ann Vasc Surg 17: 656-662, 2003.
33. Milne SA, Armstrong RA, Woodward DF. Comparison of the EP receptor subtypes mediating relaxation of the rabbit jugular and pig saphenous veins. Prostaglandins 49: 225-237, 1995.
34. Nagamatsu T, Imai H, Yokoi M, Nishiyama T, Hirasawa Y, Nagao T, Suzuki Y. Protective effect of prostaglandin EP4-receptor agonist on anti-glomerular basement membrane antibody-associated nephritis. J Pharmacol Sci 102: 182-188, 2006.
35. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 39: 930-936, 2002.
36. Omer S, Mulay S, Cernacek P, Varma DR. Attenuation of renal effects of atrial natriuretic factor during rat pregnancy. Am J Physiol Renal Fluid Electrolyte Physiol 268: F416-F422, 1995.
37. Pappenheimer JR, Karnovsky ML, Maggio JE. Absorption and excretion of undegradable peptides: role of lipid solubility and net charge. J Pharmacol Exp Ther 280: 292-300, 1997.
38. Peri KG, Quiniou C, Hou X, Abran D, Varma DR, Lubell WD, Chemtob S. THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol 26: 389-397, 2002.
39. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8: 368-379, 1986.
40. Rihakova L, Quiniou C, Hamdan F, Kaul R, Brault S, Hou X, Lahaie I, Sapieha PS, Hamel D, Shao Z, Gobeil F Jr, Hardy P, Joyal JS, Nedev H, Duhamel F, Beauregard K, Heveker N, Saragovi HU, Guillon G, Bouvier M, Lubell WD, Chemtob S. VRQ397 (CRAVKY): a novel non-competitive V2 receptor antagonist. Am J Physiol Regul Integr Comp Physiol 297: R1009-R1018, 2009.
41. Schweda F, Klar J, Narumiya S, Nusing RM, Kurtz A. Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. Am J Physiol Renal Physiol 287: F427-F433, 2004.
42. Stitham J, Stojanovic A, Merenick BL, O'Hara KA, Hwa J. The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. J Biol Chem 278: 4250-4257, 2003.
43. Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P. Differential gene expression following early renal ischemia/reperfusion. Kidney Int 63: 1714-1724, 2003.
44. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 334: 1448-1460, 1996.
45. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13, 2007.
46. Venkataraman R, Kellum JA. Prevention of acute renal failure. Chest 131: 300-308, 2007.
47. Villanueva S, Cespedes C, Gonzalez AA, Roessler E, Vio CP. Inhibition of bFGF-receptor type 2 increases kidney damage and suppresses nephrogenic protein expression after ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 294: R819-R828, 2008.
48. Villanueva S, Cespedes C, Vio CP. Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol Regul Integr Comp Physiol 290: R861-R870, 2006.
49. Vukicevic S, Simic P, Borovecki F, Grgurevic L, Rogic D, Orlic I, Grasser WA, Thompson DD, Paralkar VM. Role of EP2 and EP4 receptor-selective agonists of prostaglandin E2 in acute and chronic kidney failure. Kidney Int 70: 1099-1106, 2006.
50. Wilson RJ, Giles H. Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes. Br J Pharmacol 144: 405-415, 2005.
51. Young RN, Billot X, Han Y, Slipetz DA, Chauret N, Belley M, Metters K, Mathieu MC, Greig GM, Denis D, Girard M. Discovery and synthesis of a potent, selective and orally bioavailable EP4 receptor agonist. Heterocycles 64: 437-446, 2004.
52. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, Chen H, Jenner R, Herbolsheimer E, Jacobsen E, Kadam S, Ecker JR, Emerson B, Hogenesch JB, Unterman T, Young RA, Montminy M. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci USA 102: 4459-4464, 2005.